<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31704179</PMID><DateCompleted><Year>2020</Year><Month>09</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-108X</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>12</Issue><PubDate><Year>2019</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Trends in neurosciences</Title><ISOAbbreviation>Trends Neurosci</ISOAbbreviation></Journal><ArticleTitle>Lysosomal Dysfunction at the Centre of Parkinson's Disease and Frontotemporal Dementia/Amyotrophic Lateral Sclerosis.</ArticleTitle><Pagination><StartPage>899</StartPage><EndPage>912</EndPage><MedlinePgn>899-912</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.tins.2019.10.002</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0166-2236(19)30181-X</ELocationID><Abstract><AbstractText>Parkinson's disease (PD) and frontotemporal dementia/amyotrophic lateral sclerosis (FTD/ALS) are insidious and incurable neurodegenerative diseases that represent a significant burden to affected individuals, caregivers, and an ageing population. Both PD and FTD/ALS are defined at post mortem by the presence of protein aggregates and the loss of specific subsets of neurons. We examine here the crucial role of lysosome dysfunction in these diseases and discuss recent evidence for converging mechanisms. This review draws upon multiple lines of evidence from genetic studies, human tissue, induced pluripotent stem cells (iPSCs), and animal models to argue that lysosomal failure is a primary mechanism of disease, rather than merely reflecting association with protein aggregate end-points. This review provides compelling rationale for targeting lysosomes in future therapeutics for both PD and FTD/ALS.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wallings</LastName><ForeName>Rebecca L</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>Department of Physiology, Emory University, Decatur, GA, USA; Current address: Department of Neuroscience, Center for Translational Research and Neurodegenerative Disease, McKnight Brain Institute, University of Florida, Gainesville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Humble</LastName><ForeName>Stewart W</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>Oxford Parkinson's Disease Centre, Department of Physiology Anatomy and Genetics, University of Oxford, South Parks Road, Oxford, OX1 3QX, UK; National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ward</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wade-Martins</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Oxford Parkinson's Disease Centre, Department of Physiology Anatomy and Genetics, University of Oxford, South Parks Road, Oxford, OX1 3QX, UK. Electronic address: richard.wade-martins@dpag.ox.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/L023784/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>H-1102</GrantID><Acronym>PUK_</Acronym><Agency>Parkinson's UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/M024962/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>J-0901</GrantID><Acronym>PUK_</Acronym><Agency>Parkinson's UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>ZIA NS003155</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MC_EX_MR/N50192X/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L023784/2</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>Z99 NS999999</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>11</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Trends Neurosci</MedlineTA><NlmUniqueID>7808616</NlmUniqueID><ISSNLinking>0166-2236</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008247" MajorTopicYN="N">Lysosomes</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Parkinson&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">autophagy</Keyword><Keyword MajorTopicYN="N">frontotemporal dementia</Keyword><Keyword MajorTopicYN="N">lysosomes</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>7</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>9</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>10</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>11</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>11</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31704179</ArticleId><ArticleId IdType="mid">NIHMS1542246</ArticleId><ArticleId IdType="pmc">PMC6931156</ArticleId><ArticleId IdType="doi">10.1016/j.tins.2019.10.002</ArticleId><ArticleId IdType="pii">S0166-2236(19)30181-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>DeJesus-Hernandez M et al. (2011) Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72, 245&#x2013;256</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE et al. (2011) A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72, 257&#x2013;268</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Kertesz AP et al. (2011) Extrapyramidal syndromes in frontotemporal degeneration. J. Mol. Neurosci 45, 336&#x2013;342</Citation><ArticleIdList><ArticleId IdType="pubmed">21887521</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourinaris T and Houlden H (2018) C9orf72 and its relevance in parkinsonism and movement disorders: a comprehensive review of the literature. Mov. Disord. Clin. Pract 5, 575&#x2013;585</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6277362</ArticleId><ArticleId IdType="pubmed">30637277</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton M et al. (1998)Association of missense and 5&#x2032;-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393, 702&#x2013;705</Citation><ArticleIdList><ArticleId IdType="pubmed">9641683</ArticleId></ArticleIdList></Reference><Reference><Citation>Baizabal-Carvallo JF and Jankovic J (2016) Parkinsonism, movement disorders and genetics in frontotemporal dementia. Nat. Rev. Neurol 12, 175&#x2013;185</Citation><ArticleIdList><ArticleId IdType="pubmed">26891767</ArticleId></ArticleIdList></Reference><Reference><Citation>Park HK et al. (2017) Clinical characteristics of parkinsonism in frontotemporal dementia according to subtypes. J. Neurol. Sci 372, 51&#x2013;56</Citation><ArticleIdList><ArticleId IdType="pubmed">28017247</ArticleId></ArticleIdList></Reference><Reference><Citation>Lebedev AV et al. (2014) Large-scale resting state network correlates of cognitive impairment in Parkinson&#x2019;s disease and related dopaminergic deficits. Front. Syst. Neurosci 8, 45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3982053</ArticleId><ArticleId IdType="pubmed">24765065</ArticleId></ArticleIdList></Reference><Reference><Citation>Lashley T et al. (2015) Review: an update on clinical, genetic and pathological aspects of frontotemporal lobar degenerations. Neuropathol. Appl. Neurobiol 41, 858&#x2013;881</Citation><ArticleIdList><ArticleId IdType="pubmed">26041104</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang D et al. (2017) A meta-analysis of genome-wide association studies identifies 17 new Parkinson&#x2019;s disease risk loci. Nat. Genet 49, 1511&#x2013;1516</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5812477</ArticleId><ArticleId IdType="pubmed">28892059</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalls MA et al. (2019) Expanding Parkinson&#x2019;s disease genetics: novel risk loci, genomic context, causal insights and heritable risk. bioRxiv. Published online February 11, 2019. 10.1101/388165</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/388165</ArticleId></ArticleIdList></Reference><Reference><Citation>Platt FM et al. (2018) Lysosomal storage diseases. Nat. Rev. Dis. Primers 4, 27.</Citation><ArticleIdList><ArticleId IdType="pubmed">30275469</ArticleId></ArticleIdList></Reference><Reference><Citation>Denis JA et al. (2013) mTOR-dependent proliferation defect in human ES-derived neural stem cells affected by myotonic dystrophy type 1. J. Cell Sci 126, 1763&#x2013;1772</Citation><ArticleIdList><ArticleId IdType="pubmed">23444380</ArticleId></ArticleIdList></Reference><Reference><Citation>Robak LA et al. (2017) Excessive burden of lysosomal storage disorder gene variants in Parkinson&#x2019;s disease. Brain 140, 3191&#x2013;3203</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5841393</ArticleId><ArticleId IdType="pubmed">29140481</ArticleId></ArticleIdList></Reference><Reference><Citation>Dagan E et al. (2015)The contribution of Niemann-Pick SMPD1 mutations to Parkinson disease in Ashkenazi Jews. Parkinsonism Relat. Disord 21, 1067&#x2013;1071</Citation><ArticleIdList><ArticleId IdType="pubmed">26169695</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling S-C et al. (2013) Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron 79, 416&#x2013;438</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4411085</ArticleId><ArticleId IdType="pubmed">23931993</ArticleId></ArticleIdList></Reference><Reference><Citation>Amick J and Ferguson SM (2017) C9orf72: at the intersection of lysosome cell biology and neurodegenerative disease. Traffic 18, 267&#x2013;276</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5389918</ArticleId><ArticleId IdType="pubmed">28266105</ArticleId></ArticleIdList></Reference><Reference><Citation>Amick JA et al. (2016) C9orf72 binds SMCR8, localizes to lysosomes, and regulates mTORC1 signaling. Mol. Biol. Cell 27, 3040&#x2013;3051</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5063613</ArticleId><ArticleId IdType="pubmed">27559131</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C et al. (2018) Endo-lysosomal dysfunction: a converging mechanism in neurodegenerative diseases. Curr. Opin. Neurobiol 48, 52&#x2013;58</Citation><ArticleIdList><ArticleId IdType="pubmed">29028540</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G et al. (2018) Association of GALC, ZNF184, IL1R2 and ELOVL7 With Parkinson&#x2019;s disease in southern Chinese. Front. Aging Neurosci 10, 402.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6301214</ArticleId><ArticleId IdType="pubmed">30618709</ArticleId></ArticleIdList></Reference><Reference><Citation>Haak T et al. (2016) Absence of the autophagy adaptor SQSTM1/p62 causes childhood-onset neurodegeneration with ataxia, dystonia, and gaze palsy. Am. J. Hum. Genet 99, 735&#x2013;743</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5010644</ArticleId><ArticleId IdType="pubmed">27545679</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrari R et al. (2018) Stratification of candidate genes for Parkinson&#x2019;s disease using weighted protein&#x2013;protein interaction network analysis. BMC Genom. 19, 452</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6000968</ArticleId><ArticleId IdType="pubmed">29898659</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao C et al. (2019) CHCHD10 is involved in the development of Parkinson&#x2019;s disease caused by CHCHD2 loss-of-function mutation p.T61I. Neurobiol. Aging 75, 38&#x2013;41</Citation><ArticleIdList><ArticleId IdType="pubmed">30530185</ArticleId></ArticleIdList></Reference><Reference><Citation>Puska G et al. (2018) Lysosomal response in relation to alpha-synuclein pathology differs between Parkinson&#x2019;s disease and multiple system atrophy. Neurobiol. Dis 114, 140&#x2013;152</Citation><ArticleIdList><ArticleId IdType="pubmed">29505813</ArticleId></ArticleIdList></Reference><Reference><Citation>Beel S et al. (2017) Progranulin functions as a cathepsin D chaperone to stimulate axonal outgrowth in vivo. Hum. Mol. Genet 26, 2850&#x2013;2863</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5886064</ArticleId><ArticleId IdType="pubmed">28453791</ArticleId></ArticleIdList></Reference><Reference><Citation>Thottath J et al. (2019) A novel cathepsin D mutation in 2 siblings with late infantile neuronal ceroid lipofuscinosis. Neurol. Genet 5, e302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6481222</ArticleId><ArticleId IdType="pubmed">31086824</ArticleId></ArticleIdList></Reference><Reference><Citation>Ketterer S et al. (2017) Inherited diseases caused by mutations in cathepsin protease genes. FEBS J. 284, 1437&#x2013;1454</Citation><ArticleIdList><ArticleId IdType="pubmed">27926992</ArticleId></ArticleIdList></Reference><Reference><Citation>Taguchi YV et al. (2017) Glucosylsphingosine promotes alpha-synuclein pathology in mutant GBA-associated Parkinson&#x2019;s disease. J. Neurosci 37, 9617&#x2013;9631</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5628407</ArticleId><ArticleId IdType="pubmed">28847804</ArticleId></ArticleIdList></Reference><Reference><Citation>Do CB et al. (2011) Web-based genome-wide association study identifies two novel loci and a substantial genetic component for Parkinson&#x2019;s disease. PLoS Genet. 7, e1002141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3121750</ArticleId><ArticleId IdType="pubmed">21738487</ArticleId></ArticleIdList></Reference><Reference><Citation>Hugo et al. (2016) ER Stress and autophagic perturbations lead to elevated extracellular &#x3b1;-synuclein in GBA-N370S Parkinson&#x2019;s iPSC-derived dopamine neurons. Stem Cell Rep. 6, 342&#x2013;356</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4788783</ArticleId><ArticleId IdType="pubmed">26905200</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez A et al. (2006) Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat. Genet 38, 1184&#x2013;1191</Citation><ArticleIdList><ArticleId IdType="pubmed">16964263</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato S et al. (2016) Lysosomal storage of subunit c of mitochondrial ATP synthase in brain-specific Atp13a2-deficient mice. Am. J. Pathol 186, 3074&#x2013;3082</Citation><ArticleIdList><ArticleId IdType="pubmed">27770614</ArticleId></ArticleIdList></Reference><Reference><Citation>Holemans T et al. (2015) A lipid switch unlocks Parkinson&#x2019;s disease-associated ATP13A2. Proc. Natl. Acad. Sci. U S A 112, 9040&#x2013;9045</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4517210</ArticleId><ArticleId IdType="pubmed">26134396</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster CP et al. (2016) The C9orf72 protein interacts with Rab1a and the ULK1 complex to regulate initiation of autophagy. EMBO J. 35,1656&#x2013;1676</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4969571</ArticleId><ArticleId IdType="pubmed">27334615</ArticleId></ArticleIdList></Reference><Reference><Citation>Sellier C et al. (2016) Loss of C9ORF72 impairs autophagy and synergizes with polyQ Ataxin-2 to induce motor neuron dysfunction and cell death. EMBO J. 35, 1276&#x2013;1297</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4910533</ArticleId><ArticleId IdType="pubmed">27103069</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoki Y et al. (2017) C9orf72 and RAB7L1 regulate vesicle trafficking in amyotrophic lateral sclerosis and frontotemporal dementia. Brain 140, 887&#x2013;897</Citation><ArticleIdList><ArticleId IdType="pubmed">28334866</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida S et al. (2013) Modeling key pathological features of frontotemporal dementia with C9ORF72 repeat expansion in iPSC-derived human neurons. Acta Neuropathol. 126, 385&#x2013;399</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3753484</ArticleId><ArticleId IdType="pubmed">23836290</ArticleId></ArticleIdList></Reference><Reference><Citation>Chitiprolu M et al. (2018) A complex of C9ORF72 and p62 uses arginine methylation to eliminate stress granules by autophagy. Nat. Commun 9, 2794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6052026</ArticleId><ArticleId IdType="pubmed">30022074</ArticleId></ArticleIdList></Reference><Reference><Citation>Bussi C et al. (2018) Alpha-synuclein fibrils recruit TBK1 and OPTN to lysosomal damage sites and induce autophagy in microglial cells. J. Cell Sci 131, jcs226241.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6518333</ArticleId><ArticleId IdType="pubmed">30404831</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C-H et al. (2012) Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis. Nature 488, 499&#x2013;503</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3575525</ArticleId><ArticleId IdType="pubmed">22801503</ArticleId></ArticleIdList></Reference><Reference><Citation>Nekouei M et al. (2018) Changes in biophysical characteristics of PFN1 due to mutation causing amyotrophic lateral sclerosis. Metab. Brain Dis 33, 1975&#x2013;1984</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6230493</ArticleId><ArticleId IdType="pubmed">30203378</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka Y et al. (2016) Gain-of-function profilin 1 mutations linked to familial amyotrophic lateral sclerosis cause seed-dependent intracellular TDP-43 aggregation. Hum. Mol. Genet 25, 1420&#x2013;1433</Citation><ArticleIdList><ArticleId IdType="pubmed">26908597</ArticleId></ArticleIdList></Reference><Reference><Citation>Danieli A and Martens S (2018) p62-mediated phase separation at the intersection of the ubiquitin-proteasome system and autophagy. J. Cell Sci 131, jcs214304.</Citation><ArticleIdList><ArticleId IdType="pubmed">30287680</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;tzl JK et al. (2016) Impaired protein degradation in FTLD and related disorders. Ageing Res. Rev 32, 122&#x2013;139</Citation><ArticleIdList><ArticleId IdType="pubmed">27166223</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y et al. (2019) The cargo receptor SQSTM1 ameliorates neurofibrillary tangle pathology and spreading through selective targeting of pathological MAPT (microtubule associated protein tau). Autophagy 15, 583&#x2013;598</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6526869</ArticleId><ArticleId IdType="pubmed">30290707</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Den Boom J and Meyer H (2018) VCP/p97-mediated unfolding as a principle in protein homeostasis and signaling. Mol. Cell 69, 182&#x2013;194</Citation><ArticleIdList><ArticleId IdType="pubmed">29153394</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju J-S et al. (2009) Vasolin-containing protein (VCP) is required for autophagy and is disrupted in VCP disease. J. Cell Biol 187, 875&#x2013;888</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2806317</ArticleId><ArticleId IdType="pubmed">20008565</ArticleId></ArticleIdList></Reference><Reference><Citation>Tresse E et al. (2010) VCP/p97 is essential for maturation of ubiquitin-containing autophagosomes and this function is impaired by mutations that cause IBMPFD. Autophagy 6, 217&#x2013;227</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2929010</ArticleId><ArticleId IdType="pubmed">20104022</ArticleId></ArticleIdList></Reference><Reference><Citation>Bento AC et al. (2018) UBXD1 is a mitochondrial recruitment factor for p97/VCP and promotes mitophagy. Sci. Rep 8, 12415.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6098094</ArticleId><ArticleId IdType="pubmed">30120381</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim NC et al. (2013) VCP Is essential for mitochondrial quality control by PINK1/Parkin and this function is impaired by VCP mutations. Neuron 78, 65&#x2013;80</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3683300</ArticleId><ArticleId IdType="pubmed">23498974</ArticleId></ArticleIdList></Reference><Reference><Citation>Papadopoulos C et al. (2017) VCP/p97 cooperates with YOD1, UBXD1 and PLAA to drive clearance of ruptured lysosomes by autophagy. EMBO J. 36, 135&#x2013;150</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5242375</ArticleId><ArticleId IdType="pubmed">27753622</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry AG et al. (2015) Pathogenic LRRK2 mutations, through increased kinase activity, produce enlarged lysosomes with reduced degradative capacity and increase ATP13A2 expression. Hum. Mol. Genet 24, 6013&#x2013;6028</Citation><ArticleIdList><ArticleId IdType="pubmed">26251043</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallings RN et al. (2019) LRRK2 interacts with the vacuolar-type H+-ATPase pump a1 subunit to regulate lysosomal function. Hum. Mol. Genet 28, 2696&#x2013;2710</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6687951</ArticleId><ArticleId IdType="pubmed">31039583</ArticleId></ArticleIdList></Reference><Reference><Citation>Jinn S et al. (2017) TMEM175 deficiency impairs lysosomal and mitochondrial function and increases alpha-synuclein aggregation. Proc. Natl. Acad. Sci. U S A 114, 2389&#x2013;2394</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5338534</ArticleId><ArticleId IdType="pubmed">28193887</ArticleId></ArticleIdList></Reference><Reference><Citation>Bento CF et al. (2016) The Parkinson&#x2019;s disease-associated genes ATP13A2 and SYT11 regulate autophagy via a common pathway. Nat. Commun 7, 11803.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4906231</ArticleId><ArticleId IdType="pubmed">27278822</ArticleId></ArticleIdList></Reference><Reference><Citation>Salazar DA et al. (2015) The progranulin cleavage products, granulins, exacerbate TDP-43 toxicity and increase TDP-43 levels. J. Neurosci 35, 9315&#x2013;9328</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4478251</ArticleId><ArticleId IdType="pubmed">26109656</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia Q et al. (2016) TDP-43 loss of function increases TFEB activity and blocks autophagosome-lysosome fusion. EMBO J. 35, 121&#x2013;142</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4718457</ArticleId><ArticleId IdType="pubmed">26702100</ArticleId></ArticleIdList></Reference><Reference><Citation>Holler CJ et al. (2017) Intracellular proteolysis of progranulin generates stable, lysosomal granulins that are haploinsufficient in patients with frontotemporal dementia caused by GRN mutations. eNeuro 4, ENEURO.0100&#x2013;17.2017</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5562298</ArticleId><ArticleId IdType="pubmed">28828399</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka Y et al. (2017) Progranulin regulates lysosomal function and biogenesis through acidification of lysosomes. Hum. Mol. Genet 26, 969&#x2013;988</Citation><ArticleIdList><ArticleId IdType="pubmed">28073925</ArticleId></ArticleIdList></Reference><Reference><Citation>Pottier C et al. (2018) Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurol. 17, 548&#x2013;558</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6237181</ArticleId><ArticleId IdType="pubmed">29724592</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein ZA et al. (2017) Loss of TMEM106B ameliorates lysosomal and frontotemporal dementia-related phenotypes in progranulin-deficient mice. Neuron 95, 281&#x2013;296</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5558861</ArticleId><ArticleId IdType="pubmed">28728022</ArticleId></ArticleIdList></Reference><Reference><Citation>Clayton EL et al. (2018) Frontotemporal dementia causative CHMP2B impairs neuronal endolysosomal traffic-rescue by TMEM106B knockdown. Brain 141, 3428&#x2013;3442</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6262218</ArticleId><ArticleId IdType="pubmed">30496365</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiral FR et al. (2018) Rab GTPases and membrane trafficking in neurodegeneration. Curr. Biol 28, R471&#x2013;R486</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5965285</ArticleId><ArticleId IdType="pubmed">29689231</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson G et al. (2014) Mutations in RAB39B cause X-linked intellectual disability and early-onset Parkinson disease with &#x3b1;-synuclein pathology. Am. J. Hum. Genet 95, 729&#x2013;735</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4259921</ArticleId><ArticleId IdType="pubmed">25434005</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z et al. (2018) LRRK2 phosphorylates membrane-bound Rabs and is activated by GTP-bound Rab7L1 to promote recruitment to the trans-Golgi network. Hum. Mol. Genet 27, 385&#x2013;395</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5886198</ArticleId><ArticleId IdType="pubmed">29177506</ArticleId></ArticleIdList></Reference><Reference><Citation>Steger M et al. (2017) Systematic proteomic analysis of LRRK2-mediated Rab GTPase phosphorylation establishes a connection to ciliogenesis. eLife 6, e31012.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5695910</ArticleId><ArticleId IdType="pubmed">29125462</ArticleId></ArticleIdList></Reference><Reference><Citation>Steger M et al. (2016) Phosphoproteomics reveals that Parkinson&#x2019;s disease kinase LRRK2 regulates a subset of Rab GTPases. eLife 5, e12813.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4769169</ArticleId><ArticleId IdType="pubmed">26824392</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujimoto T et al. (2018) Parkinson&#x2019;s disease-associated mutant LRRK2 phosphorylates Rab7L1 and modifies trans-Golgi morphology. Biochem. Biophys. Res. Commun 495, 1708&#x2013;1715</Citation><ArticleIdList><ArticleId IdType="pubmed">29223392</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuwahara T et al. (2016) LRRK2 and RAB7L1 coordinately regulate axonal morphology and lysosome integrity in diverse cellular contexts. Sci. Rep 6, 29945.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4947924</ArticleId><ArticleId IdType="pubmed">27424887</ArticleId></ArticleIdList></Reference><Reference><Citation>Purlyte E et al. (2018) Rab29 activation of the Parkinson&#x2019;s disease-associated LRRK2 kinase. EMBO J. 37, 1&#x2013;18</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5753036</ArticleId><ArticleId IdType="pubmed">29212815</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanning NJ et al. (2018) LRRK2 deficiency impairs trans-Golgi to lysosome trafficking and endocytic cargo degradation in human renal proximal tubule epithelial cells. Am. J. Physiol. Renal Physiol 315, F1465&#x2013;F1477</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6293309</ArticleId><ArticleId IdType="pubmed">30089035</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu M et al. (2018) LRRK2 mediated Rab8a phosphorylation promotes lipid storage. Lipids Health Dis. 17, 34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5828482</ArticleId><ArticleId IdType="pubmed">29482628</ArticleId></ArticleIdList></Reference><Reference><Citation>Eguchi T et al. (2018) LRRK2 and its substrate Rab GTPases are sequentially targeted onto stressed lysosomes and maintain their homeostasis. Proc. Natl. Acad. Sci. U S A 115, E9115&#x2013;E9124</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6166828</ArticleId><ArticleId IdType="pubmed">30209220</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim MJ et al. (2017) The Parkinson&#x2019;s disease-linked protein TMEM230 is required for Rab8a-mediated secretory vesicle trafficking and retromer trafficking. Hum. Mol. Genet 26, 729&#x2013;741</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6251589</ArticleId><ArticleId IdType="pubmed">28115417</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai YC et al. (2015) Phosphoproteomic screening identifies Rab GTPases as novel downstream targets of PINK1. EMBO J. 34, 2840&#x2013;2861</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4654935</ArticleId><ArticleId IdType="pubmed">26471730</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheehan P et al. (2016) Activity-dependent degradation of synaptic vesicle proteins requires Rab35 and the ESCRT pathway. J. Neurosci 36, 8668&#x2013;8686</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4987437</ArticleId><ArticleId IdType="pubmed">27535913</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadano S et al. (2010) Loss of ALS2/Alsin exacerbates motor dysfunction in a SOD1H46R-expressing mouse ALS model by disturbing endolysosomal trafficking. PLoS One 5, e9805.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2842444</ArticleId><ArticleId IdType="pubmed">20339559</ArticleId></ArticleIdList></Reference><Reference><Citation>Richter B et al. (2016) Phosphorylation of OPTN by TBK1 enhances its binding to Ub chains and promotes selective autophagy of damaged mitochondria. Proc. Natl. Acad. Sci. U S A 113, 4039&#x2013;4044</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4839414</ArticleId><ArticleId IdType="pubmed">27035970</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore AS and Holzbaur EL (2016) Dynamic recruitment and activation of ALS-associated TBK1 with its target optineurin are required for efficient mitophagy. Proc. Natl. Acad. Sci. U S A 113, E3349&#x2013;E3358</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4914160</ArticleId><ArticleId IdType="pubmed">27247382</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong YC and Holzbaur ELF (2014) Optineurin is an autophagy receptor for damaged mitochondria in parkin-mediated mitophagy that is disrupted by an ALS-linked mutation. Proc. Natl. Acad. Sci. U S A 111, E4439&#x2013;E4448</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4210283</ArticleId><ArticleId IdType="pubmed">25294927</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller S and Muqit MMK (2019) Therapeutic approaches to enhance PINK1/Parkin mediated mitophagy for the treatment of Parkinson&#x2019;s disease. Neurosci. Lett 705, 7&#x2013;13</Citation><ArticleIdList><ArticleId IdType="pubmed">30995519</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamano K et al. (2018) Endosomal Rab cycles regulate Parkin-mediated mitophagy. eLife 7, e31326.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5780041</ArticleId><ArticleId IdType="pubmed">29360040</ArticleId></ArticleIdList></Reference><Reference><Citation>Heo JM et al. (2018) RAB7A phosphorylation by TBK1 promotes mitophagy via the PINK&#x2013;PARKIN pathway. Sci. Adv 4, eaav0443.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6314648</ArticleId><ArticleId IdType="pubmed">30627666</ArticleId></ArticleIdList></Reference><Reference><Citation>Funayama M et al. (2015) CHCHD2 mutations in autosomal dominant late-onset Parkinson&#x2019;s disease: a genome-wide linkage and sequencing study. Lancet Neurol. 14, 274&#x2013;282</Citation><ArticleIdList><ArticleId IdType="pubmed">25662902</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaussenot A et al. (2014) Screening of CHCHD10 in a French cohort confirms the involvement of this gene in frontotemporal dementia with amyotrophic lateral sclerosis patients. Neurobiol. Aging 35, 2884.e1&#x2013;2884.e4</Citation><ArticleIdList><ArticleId IdType="pubmed">25155093</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang X et al. (2018) CHCHD2 accumulates in distressed mitochondria and facilitates oligomerization of CHCHD10. Hum. Mol. Genet 27, 3881&#x2013;3900</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6216204</ArticleId><ArticleId IdType="pubmed">30084972</ArticleId></ArticleIdList></Reference><Reference><Citation>Woo J-AA et al. (2017) Loss of function CHCHD10 mutations in cytoplasmic TDP-43 accumulation and synaptic integrity. Nat. Commun 8, 15558.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5467170</ArticleId><ArticleId IdType="pubmed">28585542</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu JW et al. (2019) Balancing apoptosis and autophagy for Parkinson&#x2019;s disease therapy: targeting BCL-2. ACS Chem. Neurosci. 10, 792&#x2013;802</Citation><ArticleIdList><ArticleId IdType="pubmed">30400738</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivero-Rios P et al. (2016) Targeting the autophagy/lysosomal degradation pathway in Parkinson&#x2019;s disease. Curr. Neuropharmacol 14, 238&#x2013;249</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4857622</ArticleId><ArticleId IdType="pubmed">26517050</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahmoradian SH et al. (2019) Lewy pathology in Parkinson&#x2019;s disease consists of crowded organelles and lipid membranes. Nat. Neurosci 22, 1099&#x2013;1109</Citation><ArticleIdList><ArticleId IdType="pubmed">31235907</ArticleId></ArticleIdList></Reference><Reference><Citation>Mamais A et al. (2018) Analysis of macroautophagy related proteins in G2019S LRRK2 Parkinson&#x2019;s disease brains with Lewy body pathology. Brain Res. 1701, 75&#x2013;84</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6361106</ArticleId><ArticleId IdType="pubmed">30055128</ArticleId></ArticleIdList></Reference><Reference><Citation>Burbulla LF et al. (2017) Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson&#x2019;s disease. Science 357, 1255&#x2013;1261</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6021018</ArticleId><ArticleId IdType="pubmed">28882997</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandor C et al. (2017) Transcriptomic profiling of purified patient-derived dopamine neurons identifies convergent perturbations and therapeutics for Parkinson&#x2019;s disease. Hum. Mol. Genet 26, 552&#x2013;566</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5409122</ArticleId><ArticleId IdType="pubmed">28096185</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng X and Yang J (2016) Lysosomal calcium in neurodegeneration. Messenger 5, 56&#x2013;66</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5659362</ArticleId><ArticleId IdType="pubmed">29082116</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Mosquera L et al. (2019) Mitochondrial respiratory chain deficiency inhibits lysosomal hydrolysis. Autophagy, 1&#x2013;20</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6693470</ArticleId><ArticleId IdType="pubmed">30917721</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzulli JR et al. (2016) Activation of &#x3b2;-glucocerebrosidase reduces pathological &#x3b1;-synuclein and restores lysosomal function in Parkinson&#x2019;s patient midbrain neurons. J. Neurosci 36, 7693&#x2013;7706</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4951575</ArticleId><ArticleId IdType="pubmed">27445146</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourdenx M et al. (2016) Nanoparticles restore lysosomal acidification defects: implications for Parkinson and other lysosomal-related diseases. Autophagy 12, 472&#x2013;483</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4835967</ArticleId><ArticleId IdType="pubmed">26761717</ArticleId></ArticleIdList></Reference><Reference><Citation>Axelsen TM and Woldbye DPD (2018) Gene therapy for Parkinson&#x2019;s disease, an update. J. Parkinsons Dis 8, 195&#x2013;215</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6027861</ArticleId><ArticleId IdType="pubmed">29710735</ArticleId></ArticleIdList></Reference><Reference><Citation>Arrant AE et al. (2018) Progranulin gene therapy improves lysosomal dysfunction and microglial pathology associated with frontotemporal dementia and neuronal ceroid lipofuscinosis. J. Neurosci 38, 2341&#x2013;2358</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5830520</ArticleId><ArticleId IdType="pubmed">29378861</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawrence RE and Zoncu R (2019) The lysosome as a cellular centre for signalling, metabolism and quality control. Nat. Cell Biol 21, 133&#x2013;142</Citation><ArticleIdList><ArticleId IdType="pubmed">30602725</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers MB (2017) Lysosomes Take Center Stage in Parkinson&#x2019;s and Frontotemporal Dementia. Alzforum</Citation></Reference><Reference><Citation>Hill AB (1965) The environment and disease: association or causation? Proc. R Soc. Med 58, 295&#x2013;300</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1898525</ArticleId><ArticleId IdType="pubmed">14283879</ArticleId></ArticleIdList></Reference><Reference><Citation>Espay AJ et al. (2019) Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. Neurology 92, 329&#x2013;337</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6382364</ArticleId><ArticleId IdType="pubmed">30745444</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu HJ et al. (2018) Selective vulnerability in neurodegenerative diseases. Nat. Neurosci 21, 1350&#x2013;1358</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6360529</ArticleId><ArticleId IdType="pubmed">30250262</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong YCD et al. (2018) Mitochondria-lysosome contacts regulate mitochondrial fission via RAB7 GTP hydrolysis. Nature 554, 382&#x2013;386</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6209448</ArticleId><ArticleId IdType="pubmed">29364868</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge W et al. (2015) The roles of lysosomes in inflammation and autoimmune diseases. Int. Rev. Immunol 34, 415&#x2013;431</Citation><ArticleIdList><ArticleId IdType="pubmed">25075736</ArticleId></ArticleIdList></Reference><Reference><Citation>He Y et al. (2011) Identification of a lysosomal pathway that modulates glucocorticoid signaling and the inflammatory response. Sci. Signal 4, ra44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3684214</ArticleId><ArticleId IdType="pubmed">21730326</ArticleId></ArticleIdList></Reference><Reference><Citation>Dzamko NCL et al. (2015) Inflammation is genetically implicated in Parkinson&#x2019;s disease. Neuroscience 302, 89&#x2013;102</Citation><ArticleIdList><ArticleId IdType="pubmed">25450953</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu C-H et al. (2016) Systemic inflammatory response and neuromuscular involvement in amyotrophic lateral sclerosis. Neurol. Neuroimmunol. Neuroinflamm 3, e244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4897985</ArticleId><ArticleId IdType="pubmed">27308305</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>